Solid Biosciences Inc. (SLDB) News
Filter SLDB News Items
SLDB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SLDB News Highlights
- For SLDB, its 30 day story count is now at 3.
- Over the past 2 days, the trend for SLDB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- GENE, DEC and DRUG are the most mentioned tickers in articles about SLDB.
Latest SLDB News From Around the Web
Below are the latest news stories about SOLID BIOSCIENCES INC that investors may wish to consider to help them evaluate SLDB as an investment opportunity.
While institutions invested in Solid Biosciences Inc. (NASDAQ:SLDB) benefited from last week's 68% gain, private equity firms stood to gain the mostKey Insights The considerable ownership by private equity firms in Solid Biosciences indicates that they collectively... |
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock UpSolid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy. |
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003– Next-generation gene transfer therapy to treat Duchenne receives FDA Fast Track Designation – CHARLESTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SGT-003, the company’s next-generation Duchenne muscular dystrophy (Duchenne) gene therapy cand |
Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare ConferenceCHARLESTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Thursday, November 30, 2023, at 1:00 pm ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by click |
The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR TherapeuticsArcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog. |
Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA NodBristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector. |
Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug INDSolid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday! |
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003– Planning to initiate Phase 1/2 trial in pediatric DMD Patients – – First cohort to study patients 4 to < 6 years of age – CHARLESTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has received U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SGT-003, the company’s next-generation D |
Solid Biosciences to Participate at Jefferies London Healthcare ConferenceCHARLESTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023, at 5:00 pm GMT. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by |